CG Oncology (CGON) Shares Outstanding (2023 - 2026)
CG Oncology's (CGON) quarterly Shares Outstanding (Entity) came in at $88.0 million in Q1 2026, up 15.46% YoY from $76.2 million in Q1 2025, and up 9.07% on a QoQ basis from $80.7 million in Q4 2025.
CG Oncology (CGON) Shares Outstanding (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Shares Outstanding (Entity) data on file, last reported at $88.0 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 15.46% year-over-year to $88.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.0 million (up 15.46% YoY) and the FY2025 annual result came in at $80.7 million, up 29.11% from the prior year.
- Shares Outstanding (Entity) improved to $88.0 million in Q1 2026, from $80.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $88.0 million in Q1 2026 to a low of $3.9 million in Q1 2023.
- A 4-year average of $50.8 million and a median of $66.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) surged 1549.94% — and 2025, when it advanced 14.36%.
- Tracing CGON's Shares Outstanding (Entity) over 4 years: stood at $4.3 million in 2023, then jumped by 1343.03% to $62.5 million in 2024, then grew by 29.11% to $80.7 million in 2025, then rose by 9.07% to $88.0 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $88.0 million (Q1 2026), $80.7 million (Q4 2025), and $78.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 88.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.20 Mn |
| Mar 31, 2026 | 84.52 Mn |
| Dec 31, 2025 | 77.30 Mn |
| Sep 30, 2025 | 76.73 Mn |
| Jun 30, 2025 | 76.23 Mn |
| Mar 31, 2025 | 76.19 Mn |
| Dec 31, 2024 | 62.50 Mn |
| Sep 30, 2024 | 67.14 Mn |
| Jun 30, 2024 | 66.65 Mn |
| Mar 31, 2024 | 47.06 Mn |
| Dec 31, 2023 | 4.33 Mn |
| Sep 30, 2023 | 4.38 Mn |
| Jun 30, 2023 | 3.92 Mn |
| Mar 31, 2023 | 3.86 Mn |